Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.ajog.2023.06.033 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Tafoxiparin, a novel drug candidate for cervical ripening and labor augmentation: results from 2 randomized, placebo-controlled studies.
Am J Obstet Gynecol
March 2024
Department of Women's and Children's Health, Uppsala University, Uppsala, Sweden.
Background: Slow progression of labor is a common obstetrical problem with multiple associated complications. Tafoxiparin is a depolymerized form of heparin with a molecular structure that eliminates the anticoagulant effects of heparin. We report on 2 phase II clinical studies of tafoxiparin in primiparas.
View Article and Find Full Text PDFTafoxiparin, a novel drug candidate for cervical ripening and labor augmentation: results from 2 randomized, placebo-controlled studies: a reply.
Am J Obstet Gynecol
December 2023
Department of Women's and Children's Health, Uppsala University, Uppsala, Sweden.
Tafoxiparin, a novel drug candidate for cervical ripening and labor augmentation: a letter.
Am J Obstet Gynecol
December 2023
Director Ahuja Healthcare and Infertility Center, Faridabad, Haryana, India.
A novel treatment approach for paediatric Gorham-Stout syndrome with chylothorax.
Acta Paediatr
November 2011
Department of Clinical Sciences, Section for Paediatrics, The BUT team, Lund University, Sweden.
Aim: To expand the treatment options in paediatric Gorham-Stout syndrome (GSS) when conventional therapy is ineffective.
Method: Two children with biopsy confirmed GSS, a rare disorder with progressive lymphangiomatosis, were treated with a combination of interferon-α-2b, low anticoagulant, low molecular weight heparin, radiotherapy and surgery.
Results: The combined therapy resolved the symptoms in the acute phase, and both patients have since been free of symptoms for >2 years.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!